- Dose range
- 0.25 → 2.4 mg/wk
- Route
- Subcutaneous injection, once weekly
- Indication(s)
- Chronic weight management; CV risk reduction in obesity + CVD
Titration schedule
| Step | Dose | Duration | Notes |
|---|---|---|---|
| 1 | 0.25 mg | Weeks 1-4 | |
| 2 | 0.5 mg | Weeks 5-8 | |
| 3 | 1.0 mg | Weeks 9-12 | |
| 4 | 1.7 mg | Weeks 13-16 | |
| 5 | 2.4 mg | Week 17+ | Maintenance |
Get compounded semaglutide from NexLife
NexLife offers flat-rate compounded semaglutide at $119/mo on the 12-month plan — same monthly price across the full titration ladder. MD/DO oversight, three pharmacies named on its plan pages, Care360 coaching included.
Check NexLife Semaglutide → Full reviewImportant notes
- This FDA-approved drug dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
- FDA-approved label dosing.
- Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. FDA has warned compounders that used salt forms (semaglutide sodium and semaglutide acetate), which are not the active ingredient in any approved drug.
References
- Wegovy (brand semaglutide) prescribing information / clinical literature.
- FDA, bulk drug substances used in compounding under section 503A (interim categories), accessed October 2026.
- USP <797>: Pharmaceutical Compounding — Sterile Preparations.